Special clinical interests in theranostics, molecular imaging and translational research.
Nat graduated in medicine from the University of Western Australia and then completed a fellowship in nuclear medicine at the University of Michigan. Apart from undergraduate science, research and medical degrees, he also holds masters degrees in medicine, oncology, health service management and business administration, and is currently completing an online masters in molecular oncology with the European School of Medical Oncology.
From 2001 – 2006, Nat was the inaugural head of the Western Australian PET/cyclotron service based at Sir Charles Gairdner Hospital. He has also held head of department positions in Nuclear Medicine and Internal Medicine at Royal Perth Hospital and Fremantle Hospital.
Currently, Nat is an an adjunct clinical professor in Medicine at Curtin University and Notre Dame University Australia. He also works consultant nuclear physician and acute medicine physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch.
With a strong track record in developing clinical and research services in the public and private sectors, Nat’s research interests are in new molecular imaging and targeted therapeutic agents in neurosciences and oncology. He is the co-investigator on a number of grants, a principal investigator in several multicentre clinical trials, and a co-author on over 50 peer reviewed publications, predominantly in the areas of molecular imaging and therapy in neuroscience and oncology.
In 2015, Nat founded Theranostics Australia, now fully owned by GenesisCare, where he remains in the position of group clinical director. He is committed to expanding the field of theranostics with GenesisCare in Australia and overseas.
- Recurrent Prostate Cancer. Lenzo N, Sohi J.S, Lim T.S. Appl Radiol 2021; Jul/Aug:40-43.
- Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer. Asokendaran ME, Meyrick DP, Skelly LA, Lenzo NP, Henderson A. World J Nucl Med. 2019 Jul-Sep;18(3):232-237. doi: 10.4103/wjnm.WJNM_59_18. PMID: 31516365 Free PMC article.
- Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer. Gallyamov M, Meyrick D, Barley J, Lenzo N. Clin Kidney J. 2019 Aug 14;13(6):1049-1055. doi: 10.1093/ckj/sfz101. eCollection 2020 Dec. PMID: 33391748 Free PMC article.
- 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP. Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29. PMID: 31069008 Free PMC article.
- Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Cancer Biother Radiopharm. 2018 Sep;33(7):274-281. doi: 10.1089/cbr.2017.2403. Epub 2018 Jul 10. PMID: 29989440
- Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Lenzo NP, Meyrick D, Turner JH. Diagnostics (Basel). 2018 Feb 11;8(1):16. doi: 10.3390/diagnostics8010016. PMID: 29439481 Free PMC article. Review.
- The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A. Nucl Med Commun. 2017 Nov;38(11):956-963. doi: 10.1097/MNM.0000000000000738. PMID: 28922335